Safe Fertility vs Fresenius Medical Care AG & Co. KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Safe Fertility Group Public Company Limited (SAFE.BK)

Q3 202620 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

August 202620 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

Latest20 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

Fresenius Medical Care AG & Co. KGaA (FME.XETRA)

Q3 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

August 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

Latest20 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.